In a clinical evaluation where results from the SCoV-2 Ag Detect™ Rapid Self-Test were compared to an FDA EUA authorized molecular SARS-CoV-2 test, the SCoV-2 Ag Detect™ Rapid Self-Test correctly identified 85.7% of positive specimens and 100% of negative specimens. The performance of this test is still being studied in patients without signs and symptoms of respiratory infection and for serial testing. Performance may differ in these populations.